Agenus Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.44
- Today's High:
- $1.605
- Open Price:
- $1.56
- 52W Low:
- $1.25
- 52W High:
- $3.37
- Prev. Close:
- $1.56
- Volume:
- 3469505
Company Statistics
- Market Cap.:
- $530.37 million
- Book Value:
- -0.069
- Revenue TTM:
- $89.90 million
- Operating Margin TTM:
- -198.77%
- Gross Profit TTM:
- $113.59 million
- Profit Margin:
- -238.59%
- Return on Assets TTM:
- -25.77%
- Return on Equity TTM:
- -1890.3%
Company Profile
Agenus Inc had its IPO on 2000-02-04 under the ticker symbol AGEN.
The company operates in the Healthcare sector and Biotechnology industry. Agenus Inc has a staff strength of 441 employees.
Stock update
Shares of Agenus Inc opened at $1.56 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $1.44 - $1.61, and closed at $1.45.
This is a -7.05% slip from the previous day's closing price.
A total volume of 3,469,505 shares were traded at the close of the day’s session.
In the last one week, shares of Agenus Inc have slipped by -4.61%.
Agenus Inc's Key Ratios
Agenus Inc has a market cap of $530.37 million, indicating a price to book ratio of 218.6149 and a price to sales ratio of 8.2731.
In the last 12-months Agenus Inc’s revenue was $89.90 million with a gross profit of $113.59 million and an EBITDA of $-171984992. The EBITDA ratio measures Agenus Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Agenus Inc’s operating margin was -198.77% while its return on assets stood at -25.77% with a return of equity of -1890.3%.
In Q3, Agenus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 91%.
Agenus Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Agenus Inc’s profitability.
Agenus Inc stock is trading at a EV to sales ratio of 7.5739 and a EV to EBITDA ratio of -4.3552. Its price to sales ratio in the trailing 12-months stood at 8.2731.
Agenus Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $429.02 million
- Total Liabilities
- $173.07 million
- Operating Cash Flow
- $-15636000.00
- Capital Expenditure
- $15.72 million
- Dividend Payout Ratio
- 0%
Agenus Inc ended 2023 with $429.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $429.02 million while shareholder equity stood at $-20385000.00.
Agenus Inc ended 2023 with $0 in deferred long-term liabilities, $173.07 million in other current liabilities, 2949000.00 in common stock, $-1638814000.00 in retained earnings and $23.94 million in goodwill. Its cash balance stood at $208.35 million and cash and short-term investments were $218.23 million. The company’s total short-term debt was $15,356,000 while long-term debt stood at $0.
Agenus Inc’s total current assets stands at $251.43 million while long-term investments were $0 and short-term investments were $9.88 million. Its net receivables were $8.82 million compared to accounts payable of $39.71 million and inventory worth $0.
In 2023, Agenus Inc's operating cash flow was $-15636000.00 while its capital expenditure stood at $15.72 million.
Comparatively, Agenus Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.45
- 52-Week High
- $3.37
- 52-Week Low
- $1.25
- Analyst Target Price
- $7.06
Agenus Inc stock is currently trading at $1.45 per share. It touched a 52-week high of $3.37 and a 52-week low of $3.37. Analysts tracking the stock have a 12-month average target price of $7.06.
Its 50-day moving average was $2.07 and 200-day moving average was $2.41 The short ratio stood at 4.95 indicating a short percent outstanding of 0%.
Around 896.1% of the company’s stock are held by insiders while 6524.8% are held by institutions.
Frequently Asked Questions About Agenus Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.